QTP-101 is the novel tuberculosis vaccine after BCG vaccination. It has four antigens and a synthetic adjuvant to boost the immunity. If you are ineterested in QTP-101, please visit our web-site in English. http://quratis.com/eng/
| Website | http://www.quratis.com/ |
| Revenue | $13.9 million |
| Employees | 9 (0 on RocketReach) |
| Founded | 2016 |
| Phone | +82 43-904-7110 |
| Technologies |
JavaScript
,
HTML
,
PHP
+5 more
(view full list)
|
| Industry | Pharmaceuticals, Manufacturing General, Drug Discovery, Manufacturing, Biotechnology |
| Keywords | Vaccine Research, Tuberculosis Treatment, Vaccine Development, Immunology, Immunotherapy, Immune Response, Drug Development, Biotechnology, Pharmaceutical, Clinical Trials, Infectious Disease, Public Health, Global Health |
| Competitors | BenQ Corporation, Samsung, Sharp HealthCare, SMART Technologies, ViewSonic, Promethean, Boxlight, Nec Display Solutions of America, Inc., Seiko Epson Corporation, Mimio +39 more (view full list) |
| SIC | SIC Code 28 Companies, SIC Code 283 Companies |
| NAICS | NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Quratis employee's phone or email?
Quratis Questions
The Quratis annual revenue was $13.9 million in 2026.
The NAICS codes for Quratis are [325, 32].
The SIC codes for Quratis are [28, 283].
Related Companies
G2Crowd Trusted
300K+
Plugin Users
